Cyclooxygenase-2 (COX-2) inhibitor. Inhibits zymosan-induced prostaglandin E2 production by rat peritoneal neutrophils in vitro and adjuvant-induced arthritis in vivo. Anti-inflammatory.
|Storage||Store at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 341.33. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||2.93 mL||14.65 mL||29.3 mL|
|5 mM||0.59 mL||2.93 mL||5.86 mL|
|10 mM||0.29 mL||1.46 mL||2.93 mL|
|50 mM||0.06 mL||0.29 mL||0.59 mL|
References are publications that support the products' biological activity.
Tsuji et al (1992) Studies on antiinflammatory agents. I. Synthesis and pharmacological properties of 2'-phenoxy-methanesulfonanilide derivatives. Chem.Pharm.Bull. 40 2399 PMID: 1446362
Otani et al (2007) Effects of the COX-2 inhibitor FK3311 on ischemia-reperfusion injury in the rat lung. J.Invest.Surg. 20 175 PMID: 17613692
Nakamura et al (1993) Studies on antiinflammatory agents. III. Synthesis and pharmacological properties of metabolites of 4'-acetyl-2'-(2,4-difluorophenoxy)methanesulfonanilide (FK3311). Chem.Pharm.Bull. 41 PMID:
If you know of a relevant reference for FK 3311, please let us know.
View Related Products by Product Action
Keywords: FK 3311, supplier, Cyclooxygenase-2, COX-2, inhibitors, inhibits, Oxygenases, Oxidases, FK3311, Cyclooxygenase, Cyclooxygenase, Tocris Bioscience
Citations for FK 3311
Citations are publications that use Tocris products.
Currently there are no citations for FK 3311. Do you know of a great paper that uses FK 3311 from Tocris? If so please let us know.
FK 3311 Reviews
Average Rating:(Based on 0 Reviews)
Literature in this Area
Alzheimer's disease (AD) is a degenerative brain disease and the most common cause of dementia, affecting approximately 47 million people worldwide. Updated in 2015, this poster summarizes the structural and functional changes observed in the progression of this neurodegenerative disease, as well as classic AD drug targets.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.